ClinicalTrials.gg
CompletedNCT00473746Updated Apr 29, 2014Results posted

Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer

A Phase 1/2 interventional study of Abiraterone acetate and Abiraterone acetate in Prostate Neoplasms, sponsored by Janssen Research & Development, LLC. Completed at 3 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
43rd of 98
66 · median 56
Started
2006
with 1 other
Phase 1/2
8 of 98
none open now
Registered
1st of 98
by date
Lead sponsor
13 of 98
Janssen Research & Development, LLC

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 43rd largest by enrollment, is one of 2 that started in 2006, is one of 8 in phase 1/2, and was the 1st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).

Read the detailed description

This is an open-label (identity of assigned study drug will be known) study to evaluate the safety, pharmacokinetics (study of what the body does to a drug), pharmacodynamics (study of what a drug does to the body), and anti-tumor activities of abiraterone acetate (also known as CB7630) in patients with HRPC. The study will be conducted in 2 phases (Phase 1 and Phase 2). In the first part of the study (Phase 1), the maximum tolerated dose (MTD) of abiraterone acetate will be determined for use in the second part of the study (Phase 2) where the number of patients who achieve at least a 50% decrease in prostate specific antigen (PSA) during treatment with abiraterone acetate will be assessed (MTD from Phase 1). Abiraterone acetate will be taken orally (by mouth) in fed and fasted patients once daily. Doses of abiraterone acetate (starting at 250 mg up to a maximum of 2000 mg) will be taken for 28-day treatment periods to determine the MTD. Patients will take MTD of abiraterone acetate for up to twelve 28 day cycles (12 months; patients will be given the option of staying on abiraterone acetate treatment if they are deriving benefit). In Phase 2, prednisone or dexamethasone will be administered concurrently with abiraterone acetate. Serial pharmacokinetic and pharmacodynamic samples will be collected and safety will be monitored throughout the study.

03

Conditions studied

  • Prostate Neoplasms

Browse trials for

Keywords

  • Prostate neoplasms
  • Hormone refractory prostate cancer
  • Abiraterone acetate
  • CB7630
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1

  • confirmed adenocarcinoma of the prostate
  • No prior therapy with chemotherapy for prostate cancer
  • Ongoing gonadal androgen deprivation therapy with luteinizing hormone-releasing hormone (LHRH) analogues or orchiectomy
  • Testosterone \<50 ng/dL
  • Progressive disease after androgen deprivation
  • The presence of objective disease is NOT required for study eligibility
  • Demonstrate disease progression after antiandrogen withdrawal
  • (ECOG) performance status score = 0-1
  • Laboratory values within protocol-defined parameters
  • Systolic blood pressure \<160 mmHg and diastolic blood pressure \<110mmHg documented on at least 3 different days
  • Baseline adrenocorticotropic hormone (ACTH) stimulation test demonstrating a peak cortisol >18 µg/dL
  • Agrees to protocol-defined use of effective
  • of >=12 weeks

Phase 2

  • Same as Phase 1 criteria with addition of following criteria
  • or adjuvant chemotherapy is only allowed if the last dose is >1 year from Cycle 1 Day 1
  • Target or non-target abnormalities must be present either on screening bone scan, computed tomography or magnetic resonance imaging
  • No prior treatment with ketoconazole for the management of androgen independent prostate cancer

Exclusion criteria

Exclusion Criteria:

Phase 1

  • Therapy with other hormonal therapy, including any dose of megestrol acetate (Megace), finasteride (Proscar), dutasteride (Avodart) any herbal product known to decrease prostate specific antigen (PSA) levels (eg, saw palmetto and PC-SPES), or any systemic within 4 weeks prior to first dose of study drug
  • Initiation of bisphosphonate therapy within 4 weeks prior to first dose of study drug
  • Therapy with supplements or complementary medicines/botanicals within 4 weeks of first dose of study drug, except for any combination of the following: conventional multivitamin supplements, selenium, lycopene, soy supplements
  • Prior radiation therapy completed \<4 weeks prior to enrollment
  • Prior chemotherapy for hormone prostate cancer
  • Any currently active second , other than non-melanoma skin cancer
  • Systolic blood pressure >=160 mmHg or diastolic blood pressure >=110 mmHg measured on at least 2 occasions
  • Class III or IV congestive heart failure
  • Myocardial infarction within the 6 months prior to the first dose of study drug
  • Serious intercurrent infections or nonmalignant medical illnesses that are uncontrolled
  • Active psychiatric illnesses/social situations that would limit compliance with protocol requirements
  • Active or uncontrolled disease that may require corticosteroid therapy during study

Phase 2

  • Same as phase 1 with the following addition
  • Abnormal , including any finding which would interfere with assessment of intervals (patients with long syndrome, bundle branch blocks or hemiblocks are prohibited)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Phase I Dose Escalation

    Drug: Abiraterone acetate

  • Experimental
    Phase II Dose Treatment

    Drug: Abiraterone acetate · Drug: prednisone/prednisolone or dexamethasone

Interventions

  • The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.

  • Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.

  • Drugprednisone/prednisolone or dexamethasone

    prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate

06

What researchers measure

Primary outcomes

  1. Phase 1: Maximum Tolerated Dose (MTD) of Abiraterone Acetate

    The MTD is the highest dose of a drug or treatment that does not cause unacceptable side effects.

    Time frame: Up to Cycle 12

  2. Phase 2: Participants With Greater Than or Equal to 50 Percent Decline in Prostate Specific Antigen (PSA)

    Number of participants with greater than or equal to 50 percent decrease in PSA levels were assessed. PSA decline was evaluated according to (Prostate Specific Antigen Working Group) PSAWG criteria. Decrease in PSA levels represented improvement.

    Time frame: Up to 12 weeks from start of treatment

Secondary outcomes

  1. Phase 1: Maximum Plasma Concentration (Cmax) of Abiraterone Acetate

    Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).

    Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3.

  2. Phase 1: Time to Reach the Maximum Plasma Concentration (Tmax) of Abiraterone Acetate

    Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose)

    Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3

  3. Phase 1: Area Under the Plasma-Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Abiraterone Acetate

    Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).

    Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3

  4. Phase 1: Area Under the Plasma-Concentration-time Curve From Time 0 to Infinite Time (AUCINF_obs) of Abiraterone Acetate

    Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).

    Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3

  5. Phase 1: Terminal Half-life (HL_Lambda_z) of Abiraterone Acetate

    Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).

    Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3

  6. Phase 1: Total Body Clearance (Cl_F_obs) of Abiraterone Acetate

    Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).

    Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3

  7. Phase 1: Volume of Distribution (Vz_F_obs) of Abiraterone Acetate

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Volume of distribution is normally calculated by using equation volume of distribution =dose/initial concentration. Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).

    Time frame: At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3

  8. Phase 2: Radiographic Progression Free Survival (RAD-PFS)

    RAD-PFS is the time interval from the date of first dose of abiraterone acetate therapy to the date of death or radiographic disease progression according to the RECIST (Response Evaluation Criteria In Solid Tumors) criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Up to 12 weeks from start of treatment

  9. Phase 2: PSA Progression Free Survival (PSA-PFS)

    PSA-PFS is the time interval from the date of first dose of abiraterone acetate therapy to the date of death or the PSA progression as defined by the Prostate Specific Antigen Working Group (PSAWG) criteria.

    Time frame: Up to 12 weeks from start of treatment

  10. Phase 2: Radiographic Objective Response Rate (RAD-ORR)

    The objective response rate is defined as the proportion of participants with measurable lesions achieving a Complete Response (CR) or Partial Response (PR) based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Up to 12 weeks from start of treatment

  11. Phase 2: Time to PSA Progression

    The time interval from the date of first dose of abiraterone acetate therapy to the date of the PSA progression as defined by the PSAWG criteria.

    Time frame: Up to 12 weeks from start of treatment

  12. Phase 2: Duration of PSA Response

    Duration of PSA response was defined as the duration between the date of confirmed PSA response and subsequent PSA progression date as defined by the PSAWG criteria.

    Time frame: Up to 12 weeks from start of treatment

  13. Phase 2: Participants With Change in Eastern Cooperative Oncology Group (ECOG) Performance Status Score

    ECOG performance status score ranges from 0 to 5 where 0=fully active, perform all pre-disease activities without restriction. 1=restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature. 2=ambulatory, capable of self-care, unable to carry out any work activities, up and about more than (\>) 50% of waking hours. 3=capable of limited self-care, confined to bed or chair \>50% of waking hours. 4=completely disabled, not capable of any self-care, totally confined to bed or chair. 5=dead.

    Time frame: Up to 12 weeks from start of treatment

  14. Phase 2: Overall Survival

    Overall survival is the time interval from the date of first dose (cycle 1 day 1) of abiraterone acetate therapy to the date of death from any cause.

    Time frame: Up to Month 60

  15. Phase 2: Duration of Objective Response

    Duration of objective response was assessed only in participants who achieved a CR or PR, and measured from the first documented date of response to the first documented date of disease progression according to the RECIST criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Up to 12 weeks from start of treatment

07

Results

Posted Apr 29, 2014

Participant flow

The study was conducted between 10 July 2006 and 22 December 2012.

Period 1 (Phase 1)
Participant flow — Period 1 (Phase 1)
MilestonePhase 1 250 MG/DAYPhase 1 500 MG/DAYPhase 1 750 MG/DAYPhase 1 1000 MG/DAYPhase 2 1000 MG/DAY
Started696120
Completed00020
Not completed696100
Withdrew: Adverse event10000
Withdrew: Withdrawal by subject01000
Withdrew: Progressive disease566100
Withdrew: Symptomatic deterioration01000
Withdrew: Reason not specified01000
Period 2 (Phase 2)
Participant flow — Period 2 (Phase 2)
MilestonePhase 1 250 MG/DAYPhase 1 500 MG/DAYPhase 1 750 MG/DAYPhase 1 1000 MG/DAYPhase 2 1000 MG/DAY
Started000033
Completed00006
Not completed000027
Withdrew: Adverse event00003
Withdrew: Death00001
Withdrew: Progressive disease000020
Withdrew: Reason not specified00003

Outcome measures

PrimaryPhase 1: Maximum Tolerated Dose (MTD) of Abiraterone Acetate

The MTD is the highest dose of a drug or treatment that does not cause unacceptable side effects.

Time frame:
Up to Cycle 12
Reported as:
Number · mg/day
Phase 1: Maximum Tolerated Dose (MTD) of Abiraterone Acetate
mg/dayPhase I Dose Escalation
Phase 1: Maximum Tolerated Dose (MTD) of Abiraterone AcetateNA ± 0
PrimaryPhase 2: Participants With Greater Than or Equal to 50 Percent Decline in Prostate Specific Antigen (PSA)

Number of participants with greater than or equal to 50 percent decrease in PSA levels were assessed. PSA decline was evaluated according to (Prostate Specific Antigen Working Group) PSAWG criteria. Decrease in PSA levels represented improvement.

Time frame:
Up to 12 weeks from start of treatment
Reported as:
Number · participants
Phase 2: Participants With Greater Than or Equal to 50 Percent Decline in Prostate Specific Antigen (PSA)
participantsPhase II Dose Treatment
Confirmed26
Not Confirmed2
Total28
SecondaryPhase 1: Maximum Plasma Concentration (Cmax) of Abiraterone Acetate

Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).

Time frame:
At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3.
Reported as:
Mean · nanomoles per liter (nmol/L)
Phase 1: Maximum Plasma Concentration (Cmax) of Abiraterone Acetate
nanomoles per liter (nmol/L)Phase I Dose Escalation (250mg)Phase I Dose Escalation (500mg)Phase I Dose Escalation (750mg)Phase I Dose Escalation (1000mg)
Fasted283.000 ± 142.265330.633 ± 204.889289.533 ± 126.646509.500 ± 366.452
Fed421.000 ± 75.809676.000 ± 147.8661552.000 ± 458.0822194.250 ± 1096.914
SecondaryPhase 1: Time to Reach the Maximum Plasma Concentration (Tmax) of Abiraterone Acetate

Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose)

Time frame:
At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3
Reported as:
Mean · hour (hr)
Phase 1: Time to Reach the Maximum Plasma Concentration (Tmax) of Abiraterone Acetate
hour (hr)Phase I Dose Escalation (250mg)Phase I Dose Escalation (500mg)Phase I Dose Escalation (750mg)Phase I Dose Escalation (1000mg)
Fasted2.000 ± 0.0001.500 ± 0.5482.033 ± 0.0581.833 ± 0.408
Fed2.044 ± 0.0772.667 ± 1.1552.000 ± 0.0004.000 ± 0.000
SecondaryPhase 1: Area Under the Plasma-Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Abiraterone Acetate

Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).

Time frame:
At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3
Reported as:
Mean · hr*nmol/L
Phase 1: Area Under the Plasma-Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Abiraterone Acetate
hr*nmol/LPhase I Dose Escalation (250mg)Phase I Dose Escalation (500mg)Phase I Dose Escalation (750mg)Phase I Dose Escalation (1000mg)
Fasted1329.178 ± 699.9771625.059 ± 930.3641565.659 ± 661.2893039.937 ± 1902.697
Fed1310.715 ± 311.0413624.781 ± 1041.9278920.790 ± 3060.45713695.482 ± 5623.185
SecondaryPhase 1: Area Under the Plasma-Concentration-time Curve From Time 0 to Infinite Time (AUCINF_obs) of Abiraterone Acetate

Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).

Time frame:
At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3
Reported as:
Mean · hr*nmol/L
Phase 1: Area Under the Plasma-Concentration-time Curve From Time 0 to Infinite Time (AUCINF_obs) of Abiraterone Acetate
hr*nmol/LPhase I Dose Escalation (250mg)Phase I Dose Escalation (500mg)Phase I Dose Escalation (750mg)Phase I Dose Escalation (1000mg)
Fasted1411.268 ± 697.1831781.374 ± 986.7701665.454 ± 704.5513478.385 ± 2012.176
Fed1386.939 ± 290.2403839.804 ± 1080.8539358.743 ± 3338.60114404.387 ± 5971.041
SecondaryPhase 1: Terminal Half-life (HL_Lambda_z) of Abiraterone Acetate

Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).

Time frame:
At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3
Reported as:
Mean · hour (hr)
Phase 1: Terminal Half-life (HL_Lambda_z) of Abiraterone Acetate
hour (hr)Phase I Dose Escalation (250mg)Phase I Dose Escalation (500mg)Phase I Dose Escalation (750mg)Phase I Dose Escalation (1000mg)
Fasted5.284 ± 1.67610.591 ± 6.3377.066 ± 3.43114.361 ± 7.655
Fed5.125 ± 1.0396.913 ± 5.7207.939 ± 2.63312.454 ± 1.218
SecondaryPhase 1: Total Body Clearance (Cl_F_obs) of Abiraterone Acetate

Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).

Time frame:
At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3
Reported as:
Mean · liter per hour (l/hr)
Phase 1: Total Body Clearance (Cl_F_obs) of Abiraterone Acetate
liter per hour (l/hr)Phase I Dose Escalation (250mg)Phase I Dose Escalation (500mg)Phase I Dose Escalation (750mg)Phase I Dose Escalation (1000mg)
Fasted4288.456 ± 1319.3225440.949 ± 4844.5151518.748 ± 822.7142649.954 ± 4617.049
Fed529.606 ± 99.532391.046 ± 99.118246.643 ± 72.970231.383 ± 97.746
SecondaryPhase 1: Volume of Distribution (Vz_F_obs) of Abiraterone Acetate

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Volume of distribution is normally calculated by using equation volume of distribution =dose/initial concentration. Blood samples for pharmacokinetic (PK) measurements was taken on Day -7 at hour 0 (predose), at hours 1, 2, 4, 6, 8, and 12 (postdose). On Day -6 at 24 hour (postdose) and Day -5 at 48 hour (postdose). On Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 2 and 3 (Predose).

Time frame:
At hours 1, 2, 4, 6, 8, 12, 24 and 48 post dose and pre-dose on day 1, day 8, day 15 and day 22 cycle 1, day 1 cycle 2 and day 1 cycle 3
Reported as:
Mean · Liter (L)
Phase 1: Volume of Distribution (Vz_F_obs) of Abiraterone Acetate
Liter (L)Phase I Dose Escalation (250mg)Phase I Dose Escalation (500mg)Phase I Dose Escalation (750mg)Phase I Dose Escalation (1000mg)
Fasted653.745 ± 447.31610252.077 ± 12268.78713688.367 ± 4265.42925494.398 ± 18670.215
Fed3940.400 ± 1275.4083418.280 ± 1934.3842739.655 ± 1084.6944068.885 ± 1462.613
SecondaryPhase 2: Radiographic Progression Free Survival (RAD-PFS)

RAD-PFS is the time interval from the date of first dose of abiraterone acetate therapy to the date of death or radiographic disease progression according to the RECIST (Response Evaluation Criteria In Solid Tumors) criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Up to 12 weeks from start of treatment
Reported as:
Median · days
Phase 2: Radiographic Progression Free Survival (RAD-PFS)
daysPhase II Dose Treatment
Phase 2: Radiographic Progression Free Survival (RAD-PFS)NA (NA to NA)
SecondaryPhase 2: PSA Progression Free Survival (PSA-PFS)

PSA-PFS is the time interval from the date of first dose of abiraterone acetate therapy to the date of death or the PSA progression as defined by the Prostate Specific Antigen Working Group (PSAWG) criteria.

Time frame:
Up to 12 weeks from start of treatment
Reported as:
Median · days
Phase 2: PSA Progression Free Survival (PSA-PFS)
daysPhase II Dose Treatment
Phase 2: PSA Progression Free Survival (PSA-PFS)473 (281 to NA)
SecondaryPhase 2: Radiographic Objective Response Rate (RAD-ORR)

The objective response rate is defined as the proportion of participants with measurable lesions achieving a Complete Response (CR) or Partial Response (PR) based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Up to 12 weeks from start of treatment
Reported as:
Number · participants
Phase 2: Radiographic Objective Response Rate (RAD-ORR)
participantsPhase II Dose Treatment
Confirmed9 (38.6 to 90.9)
Not Confirmed1 (0.2 to 36.0)
SecondaryPhase 2: Time to PSA Progression

The time interval from the date of first dose of abiraterone acetate therapy to the date of the PSA progression as defined by the PSAWG criteria.

Time frame:
Up to 12 weeks from start of treatment
Reported as:
Median · days
Phase 2: Time to PSA Progression
daysPhase II Dose Treatment
Phase 2: Time to PSA Progression497 (281 to NA)
SecondaryPhase 2: Duration of PSA Response

Duration of PSA response was defined as the duration between the date of confirmed PSA response and subsequent PSA progression date as defined by the PSAWG criteria.

Time frame:
Up to 12 weeks from start of treatment
Reported as:
Median · days
Phase 2: Duration of PSA Response
daysPhase II Dose Treatment
Phase 2: Duration of PSA Response477 (283 to NA)
SecondaryPhase 2: Participants With Change in Eastern Cooperative Oncology Group (ECOG) Performance Status Score

ECOG performance status score ranges from 0 to 5 where 0=fully active, perform all pre-disease activities without restriction. 1=restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature. 2=ambulatory, capable of self-care, unable to carry out any work activities, up and about more than (\>) 50% of waking hours. 3=capable of limited self-care, confined to bed or chair \>50% of waking hours. 4=completely disabled, not capable of any self-care, totally confined to bed or chair. 5=dead.

Time frame:
Up to 12 weeks from start of treatment
Reported as:
Number · participants
Phase 2: Participants With Change in Eastern Cooperative Oncology Group (ECOG) Performance Status Score
participantsPhase II Dose Treatment
Baseline ECOG 020
Baseline ECOG 113
Baseline ECOG 20
Baseline ECOG 30
Baseline ECOG 40
Best Post-Baseline ECOG 028
Best Post-Baseline ECOG 15
Best Post-Baseline ECOG 20
Best Post-Baseline ECOG 30
Best Post-Baseline ECOG 40
SecondaryPhase 2: Overall Survival

Overall survival is the time interval from the date of first dose (cycle 1 day 1) of abiraterone acetate therapy to the date of death from any cause.

Time frame:
Up to Month 60
Reported as:
Median · days
Phase 2: Overall Survival
daysPhase II Dose Treatment
Phase 2: Overall SurvivalNA (NA to NA)
SecondaryPhase 2: Duration of Objective Response

Duration of objective response was assessed only in participants who achieved a CR or PR, and measured from the first documented date of response to the first documented date of disease progression according to the RECIST criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Up to 12 weeks from start of treatment
Reported as:
Median · days
Phase 2: Duration of Objective Response
daysPhase II Dose Treatment
Phase 2: Duration of Objective ResponseNA (253 to NA)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 250 MG/DAY—1/6 (16.7%)6/6 (100%)
Phase 1 500 MG/DAY—2/9 (22.2%)9/9 (100%)
Phase 1 750 MG/DAY—0/6 (0%)6/6 (100%)
Phase 1 1000 MG/DAY—0/12 (0%)12/12 (100%)
Phase 2 1000 MG/DAY—10/33 (30.3%)33/33 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPhase 1 250 MG/DAYPhase 1 500 MG/DAYPhase 1 750 MG/DAYPhase 1 1000 MG/DAYPhase 2 1000 MG/DAY
SyncopeNervous system disorders1/61/90/60/121/33
HypokalaemiaMetabolism and nutrition disorders0/61/90/60/121/33
Urinary Tract InfectionInfections and infestations0/60/90/60/122/33
UrosepsisInfections and infestations0/60/90/60/122/33
HaematuriaRenal and urinary disorders0/60/90/60/122/33
AnaemiaBlood and lymphatic system disorders0/60/90/60/121/33
Arrhythmia SupraventricularCardiac disorders0/60/90/60/121/33
Myocardial InfarctionCardiac disorders0/60/90/60/121/33
Ventricular ExtrasystolesCardiac disorders0/60/90/60/121/33
Oedema PeripheralGeneral disorders0/60/90/60/121/33
Most frequent other events
Showing 10 of 149
Most frequent other events
EventPhase 1 250 MG/DAYPhase 1 500 MG/DAYPhase 1 750 MG/DAYPhase 1 1000 MG/DAYPhase 2 1000 MG/DAY
FatigueGeneral disorders3/67/94/68/1216/33
HypokalaemiaMetabolism and nutrition disorders0/61/94/64/1210/33
CoughRespiratory, thoracic and mediastinal disorders1/62/94/61/125/33
HeadacheNervous system disorders0/63/92/67/123/33
DiarrhoeaGastrointestinal disorders0/64/93/64/127/33
NauseaGastrointestinal disorders1/63/91/66/125/33
Oedema PeripheralGeneral disorders1/64/90/66/129/33
HypertensionVascular disorders2/62/93/65/127/33
Abdominal PainGastrointestinal disorders1/62/92/62/123/33
ConstipationGastrointestinal disorders0/63/92/62/127/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase 1 250 MG/DAYPhase 1 500 MG/DAYPhase 1 750 MG/DAYPhase 1 1000 MG/DAYPhase 2 1000 MG/DAYTotal
Mean66.7 ± 6.1967.6 ± 6.573.2 ± 8.1872.9 ± 8.370.3 ± 8.5170.3 ± 8.05
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1 250 MG/DAYPhase 1 500 MG/DAYPhase 1 750 MG/DAYPhase 1 1000 MG/DAYPhase 2 1000 MG/DAYTotal
Female000000
Male696123366
Region of Enrollment
Region of Enrollment(participants)Phase 1 250 MG/DAYPhase 1 500 MG/DAYPhase 1 750 MG/DAYPhase 1 1000 MG/DAYPhase 2 1000 MG/DAYTotal
United States696123366
08

Study locations

3 sites
  • San Francisco, California, United States
  • Boston, Massachusetts, United States
  • Houston, Texas, United States
09

References and documents

Publications

  • Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, Ryan CJ. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer. 2014 Oct;12(5):e167-72. doi: 10.1016/j.clgc.2014.03.010. Epub 2014 Mar 28. PubMed 24787968 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2007
First posted
May 15, 2007
Start
Jun 2006
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Apr 29, 2014
Last update
Apr 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00473746
Responsible party
Sponsor
First posted
May 15, 2007
Start date
Jun 2006
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Apr 29, 2014
Last update
Apr 29, 2014

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion